K
Kymera Therapeutics
A biotechnology company pioneering a transformative new approach to treating previously untreatable diseases
At a glance
- Status
- Listed
- Listing
- IPO 2020
News
Open roles
Kymera Therapeutics in the Cambridge ecosystem
The Kymera Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- LVLilly Ventures
- AVAmgen Ventures
Atlas Venture
Series B and later9 investors entered at this stage
- RCRock Springs Capital
Wellington Management- 6C6 Dimensions Capital
- BSBain Capital Life Sciences
Janus Henderson Investors
- BPBVF Partners
Bessemer Venture Partners- RGRedmile Group
BlackRock
Source: Dealroom Talent Intelligence.
Alumni founders
Former Kymera Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
FBFortitude BiomedicinesEst. 2025
Jesse ChenUnited States
PTPAQ TherapeuticsEst. 2020
OTOrbital TherapeuticsEst. 2022
John MaraganoreUnited States
PTParthenon TherapeuticsEst. 2019Patents
98 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Kymera Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

